Loading news...
ALTO's Western production unit fuels earnings strength with premium pricing, LCFS tailwinds, and margin resilience.
ALTO's Pekin segment fuels earnings with high-margin alcohols, diversifying revenues and boosting long-term growth potential.
ALTO and GPRE both target low-carbon growth, but ALTO's diversification and lower valuation give it an edge.
ALTO's cost cuts, carbon strategies, and clean fuel tax credit push haven't been able to turn its market lead into profits yet.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effec.
ALTO eyes a turnaround after years of falling sales, shifting focus to specialty alcohols and CO2 monetization.
ALTO has soared 45% in a year and is pivoting to specialty alcohols, but valuation and returns raise caution.
Here is how Alto Ingredients (ALTO) and Fox (FOXA) have performed compared to their sector so far this year.
Aris Mining, Alto Ingredients and Mama's Creations are flagged as 2026 breakout stocks after solid gains and strong growth outlooks.
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Alto Ingredients (ALTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is how Alto Ingredients (ALTO) and Guess (GES) have performed compared to their sector so far this year.
Here is how Alto Ingredients (ALTO) and fuboTV Inc. (FUBO) have performed compared to their sector so far this year.
Renewable fuel and specialty alcohol producer Alto Ingredients reported strong third quarter results with profitability well ahead of consensus expectations: Key performance indicators like gross margin, adjusted EBITDA and free cash flow surged to new multi-year highs. Results benefited from a combination of seasonal strength, favorable export pricing, strong CO2 demand and benefits from the company's recent cost reduction and efficiency improvement initiatives.
After reaching an important support level, Alto Ingredients, Inc. (ALTO) could be a good stock pick from a technical perspective. ALTO recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Here is how Alto Ingredients (ALTO) and fuboTV Inc. (FUBO) have performed compared to their sector so far this year.
Alto Ingredients (ALTO) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to a loss of $0.04 per share a year ago.
Alto Ingredients, Inc. ( ALTO ) Q3 2025 Earnings Call November 5, 2025 5:00 PM EST Company Participants Bryon McGregor - CEO, President & Director Robert Olander - Chief Financial Officer Conference Call Participants Harriet C. Fried Eric Stine - Craig-Hallum Capital Group LLC, Research Division Sameer Joshi - H.C.
PEKIN, Ill., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Alto Ingredients, Inc. (NASDAQ: ALTO) a leading producer and distributor of specialty alcohols, renewable fuels and essential ingredients, announced it will release its third quarter 2025 financial results after the close of market on Wednesday, November 5, 2025.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that, following a successful outcome from a recent FDA meeting, it plans to accelerate the development of ALTO-207 for people with treatment resistant depression (TRD). The $50 million private placement announced today supports expanded development of ALTO-207, and.